Suppr超能文献

根据吸烟状况划分的特发性肺纤维化患者的临床特征

Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status.

作者信息

Kishaba Tomoo, Nagano Hiroaki, Nei Yuichiro, Yamashiro Shin

机构信息

Department of Respiratory Medicine, Okinawa Chubu Hospital, Uruma, Okinawa, Japan.

出版信息

J Thorac Dis. 2016 Jun;8(6):1112-20. doi: 10.21037/jtd.2016.03.89.

Abstract

BACKGROUND

Idiopathic pulmonary fibrosis (IPF) is the most common form of idiopathic interstitial pneumonias (IIPs) of unknown etiology that often affects male, elderly smokers. However, it is sometimes observed in never smokers. This study aimed to clarify the clinical characteristics of IPF in never-smoking patients compared with those in smoking patients.

METHODS

We retrospectively reviewed medical records, pulmonary function tests, and chest high-resolution computed tomography (HRCT) scan of never-smoking and smoking IPF patients from July 1, 2008 to June 30, 2013 at our hospital.

RESULTS

We identified 32 never-smoking IPF patients and 66 smoking IPF patients. Never-smoking IPF patients developed more acute exacerbation (AE) than smoking IPF patients (50% vs. 18.2%, P<0.0001). The strongest predictor of AE in never-smoking IPF was modified Medical Research Council (mMRC) breathlessness scale [Hazards ratio (HR), 2.84, P=0.006]. The median survival time of never-smoking and smoking were 18.5 (0.1-138) and 26.3 (0.1-98.4) months, P<0.0001, respectively. The Cox proportional hazard model showed that 1-year mMRC breathlessness scale (HR, 3.24, P=0.001) and gender, age, and physiology (GAP) score (HR, 1.59, P=0.029) were strong predictors of mortality in never-smoking IPF patients at our hospital.

CONCLUSIONS

In conclusion, never-smoking IPF patients developed AE more often and showed poor prognosis compared with smoking IPF patients. The 1-year mMRC breathlessness scale was an important predictor of mortality at our hospital.

摘要

背景

特发性肺纤维化(IPF)是病因不明的特发性间质性肺炎(IIP)最常见的形式,常影响男性老年吸烟者。然而,从不吸烟者中也时有发现。本研究旨在阐明从不吸烟的IPF患者与吸烟患者相比的临床特征。

方法

我们回顾性分析了2008年7月1日至2013年6月30日在我院就诊的从不吸烟和吸烟的IPF患者的病历、肺功能测试及胸部高分辨率计算机断层扫描(HRCT)。

结果

我们确定了32例从不吸烟的IPF患者和66例吸烟的IPF患者。从不吸烟的IPF患者比吸烟的IPF患者发生急性加重(AE)的频率更高(50%对18.2%,P<0.0001)。从不吸烟的IPF患者中AE的最强预测因素是改良医学研究委员会(mMRC)呼吸困难量表[风险比(HR),2.84,P=0.006]。从不吸烟和吸烟患者的中位生存时间分别为18.5(0.1-138)个月和26.3(0.1-98.4)个月,P<0.0001。Cox比例风险模型显示,1年mMRC呼吸困难量表(HR,3.24,P=0.001)以及性别、年龄和生理学(GAP)评分(HR,1.59,P=0.029)是我院从不吸烟的IPF患者死亡率的强预测因素。

结论

总之,与吸烟的IPF患者相比,从不吸烟的IPF患者发生AE的频率更高,预后较差。1年mMRC呼吸困难量表是我院死亡率的重要预测因素。

相似文献

3
Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis.
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620935774. doi: 10.1177/1753466620935774.
4
Heterogeneity of incidence and outcome of acute exacerbation in idiopathic interstitial pneumonia.
Respirology. 2016 Nov;21(8):1431-1437. doi: 10.1111/resp.12862. Epub 2016 Jul 26.
8
Clinical Characteristics Based on the New Criteria of Acute Exacerbation in Patients with Idiopathic Pulmonary Fibrosis.
Eurasian J Med. 2018 Feb;50(1):6-10. doi: 10.5152/eurasianjmed.2018.17330. Epub 2018 Feb 1.
10
Interleukin-11 in idiopathic pulmonary fibrosis: predictive value of prognosis and acute exacerbation.
J Thorac Dis. 2023 Feb 28;15(2):300-310. doi: 10.21037/jtd-22-876. Epub 2023 Jan 10.

引用本文的文献

1
The significance of periostin in the diagnosis of idiopathic pulmonary fibrosis and prediction of acute exacerbations.
J Thorac Dis. 2025 Mar 31;17(3):1364-1376. doi: 10.21037/jtd-24-1882. Epub 2025 Mar 14.
3
The link between smoking, emphysema, and fibrosis: A retrospective cohort study.
Tob Induc Dis. 2024 Jul 19;22. doi: 10.18332/tid/190689. eCollection 2024.
4
Smoking status and clinical outcome in idiopathic pulmonary fibrosis: a nationwide study.
Respir Res. 2024 Apr 29;25(1):191. doi: 10.1186/s12931-024-02819-w.
5
Environmental Causes of Idiopathic Pulmonary Fibrosis.
Int J Mol Sci. 2023 Nov 18;24(22):16481. doi: 10.3390/ijms242216481.
8
Diabetic Pneumopathy-A New Diabetes-Associated Complication: Mechanisms, Consequences and Treatment Considerations.
Front Endocrinol (Lausanne). 2021 Nov 25;12:765201. doi: 10.3389/fendo.2021.765201. eCollection 2021.
10
Targeting the AXL Receptor in Combating Smoking-related Pulmonary Fibrosis.
Am J Respir Cell Mol Biol. 2021 Jun;64(6):734-746. doi: 10.1165/rcmb.2020-0303OC.

本文引用的文献

1
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
N Engl J Med. 2014 May 29;370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub 2014 May 18.
2
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18.
4
Genetics and early detection in idiopathic pulmonary fibrosis.
Am J Respir Crit Care Med. 2014 Apr 1;189(7):770-8. doi: 10.1164/rccm.201312-2219PP.
5
Staging of acute exacerbation in patients with idiopathic pulmonary fibrosis.
Lung. 2014 Feb;192(1):141-9. doi: 10.1007/s00408-013-9530-0. Epub 2013 Nov 13.
8
Interobserver variability in the CT assessment of honeycombing in the lungs.
Radiology. 2013 Mar;266(3):936-44. doi: 10.1148/radiol.12112516. Epub 2012 Dec 6.
9
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
N Engl J Med. 2012 May 24;366(21):1968-77. doi: 10.1056/NEJMoa1113354. Epub 2012 May 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验